Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranirestat - Dainippon Sumitomo Pharma

Drug Profile

Ranirestat - Dainippon Sumitomo Pharma

Alternative Names: AS-3201; SX-3030; SX-3202

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Eisai Co Ltd; Sumitomo Dainippon Pharma
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Spiro compounds
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 09 Jul 2019 Discontinued - Phase-III for Diabetic neuropathies in Japan (PO) (Dainippon Sumitomo Pharma pipeline, May 2019)
  • 20 May 2015 Ranirestat is still in phase III trials for Diabetic neuropathies in Japan
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top